Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of MOR106
NCT02739009Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Apr 2016
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of MOR106 in atopic dermatitis (AD) (4 arms), sponsored by Galapagos NV. Primary endpoints: Treatment-Emergent Adverse Events, Deviating Physical Examination Results and 4 more. Started Apr 2016; status: completed.
02
Drugs
MOR106
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02739009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02739009.